CD47 and acute myeloid leukemia: These include the use of ion channel inhibitors such as 4-AP targeting KCNB1 in pancreatic CSCs [116], CD47-targeted therapies like anti-CD47 antibodies in AML [96,120], nanoparticle-based drug delivery systems that selectively transport ion channel modulators to CSC niches [12], and targeting ion channel-regulated signalling pathways such as Ca2+-dependent Wnt/β-catenin, Notch, and NFAT, especially when combined with conventional therapies [18].